title: Influence of antibiotic therapy on the level of selected angiogenic factors in patients with benign gynecologic tumors--preliminary report.
abstract: An increased fibrin level enhances the activity of proangiogenic factors and may contribute to tumor formation. Formation of new blood vessels during angiogenesis leads to neoplasm development through interaction with factors such as basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and interleukins. The aim of this study was to investigate the influence of perioperative antibiotic therapy in women with benign gynecological tumors with regard to basic fibroblast growth factor level, fibrinogen concentration and fibrin viscosity. The influence of clindamycin plus metronidazole therapy (group I) and cephazolin therapy (group II) on fibrinogen concentration, level of bFGF and fibrin viscosity was studied in women diagnosed with nonmalignant myomas and cysts. In patients with benign gynecologic tumors, higher bFGF levels (51.40 +/- 13.72 pg/ml), fibrinogen concentration (348.26 +/- 164.74 mg/dl) and fibrin viscosity (2.63 +/- 0.36 mPa) were observed, as compared with healthy women. There were strong indications that antiangiogenic activity occurred with both clindamycin plus metronidazole and cephazolin, although the response to these particular antibiotic therapies was different. The use of various drug therapies in groups I and II resulted in faster and delayed antiangiogenic effects, respectively. Further research is essential to provide more detailed information about the mechanisms of the induction of antiangiogenic activity by perioperative adjuvant antibiotic treatment.
authors: Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Medical University of Lodz, Poland.
authors: M
authors: M
authors: Michalska
authors: A
authors: A
authors: Palatyńska-Ulatowska
authors: A
authors: A
authors: Palatyński
authors: M
authors: M
authors: Mirowski
authors: K
authors: K
authors: Kaplińska
authors: J
authors: J
authors: Nawrot-Modranka
authors: A
authors: A
authors: Lazarenkow
mesh_terms: D000328:Adult; D000368:Aged; D042501:Angiogenic Proteins / Q000096:biosynthesis*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002437:Cefazolin / Q000494:pharmacology; D003560:Cysts / Q000378:metabolism; D005260:Female; D005337:Fibrin / Q000096:biosynthesis; D005340:Fibrinogen / Q000096:biosynthesis; D016222:Fibroblast Growth Factor 2 / Q000096:biosynthesis; D005833:Genital Neoplasms, Female / Q000378:metabolism*; D006801:Humans; D007378:Interleukins / Q000096:biosynthesis; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D009214:Myoma / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis; D014783:Viscosity; D055815:Young Adult
chemical_list: D042501:Angiogenic Proteins; D000900:Anti-Bacterial Agents; D007378:Interleukins; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; D008795:Metronidazole; D005337:Fibrin; D005340:Fibrinogen; D002437:Cefazolin